4,17-Dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione,2-[[(6-deoxy-2,3-di-O-methyl-b-D-allopyranosyl)oxy]methyl]-3-ethyl-2-hydroxy-8,10,12-trimethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-,(1R,2S,3R,6E,8S,9S,10S,12R,14E,16S)- cas no:73684-69-2

Name4,17-Dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione,2-[[(6-deoxy-2,3-di-O-methyl-b-D-allopyranosyl)oxy]methyl]-3-ethyl-2-hydroxy-8,10,12-trimethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-,(1R,2S,3R,6E,8S,9S,10S,12R,14E,16S)-
CAS73684-69-2
SynonymsMycinamicinI, 14-hydroxy-; 4,17-Dioxabicyclo[14.1.0]heptadecane, mycinamicin I deriv.;Antibiotic A 11725II; Antibiotic AR 5-2; Miporamicin; Mirosamicin; Mirosamycin;Mycinamicin II; Mycinomycin II
Molecular FormulaC37H61 N O13
Molecular Weight715.98

refractive index1.545

Safety

The safety information of  Mirosamicin (CAS NO.73684-69-2):
Poison by intraperitoneal route. Moderately toxic by subcutaneous route. When heated to decomposition it emits toxic fumes of NO_x.

The toxicity of  Mirosamicin (CAS NO.73684-69-2):

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
mouse	LD50	intraperitoneal	363mg/kg (363mg/kg)		Journal of Antibiotics. Vol. 33, Pg. 364, 1980.
mouse	LD50	oral	2gm/kg (2000mg/kg)		British UK Patent Application. Vol. #2020647A,
mouse	LD50	subcutaneous	465mg/kg (465mg/kg)		Journal of Antibiotics. Vol. 33, Pg. 364, 1980.